433 related articles for article (PubMed ID: 32487241)
1. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
2. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
J Control Release; 2024 May; ():. PubMed ID: 38744345
[TBL] [Abstract][Full Text] [Related]
3. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
6. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Blood-Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma.
Chaves C; Declèves X; Taghi M; Menet MC; Lacombe J; Varlet P; Olaciregui NG; Carcaboso AM; Cisternino S
Pharmaceutics; 2020 Apr; 12(5):. PubMed ID: 32349240
[TBL] [Abstract][Full Text] [Related]
8. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
[TBL] [Abstract][Full Text] [Related]
9. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
[TBL] [Abstract][Full Text] [Related]
12. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.
Alli S; Figueiredo CA; Golbourn B; Sabha N; Wu MY; Bondoc A; Luck A; Coluccia D; Maslink C; Smith C; Wurdak H; Hynynen K; O'Reilly M; Rutka JT
J Control Release; 2018 Jul; 281():29-41. PubMed ID: 29753957
[TBL] [Abstract][Full Text] [Related]
13. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
[TBL] [Abstract][Full Text] [Related]
14. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance Imaging-Guided Focused Ultrasound-Based Delivery of Radiolabeled Copper Nanoclusters to Diffuse Intrinsic Pontine Glioma.
Zhang X; Ye D; Yang L; Yue Y; Sultan D; Pacia CP; Pang H; Detering L; Heo GS; Luehmann H; Choksi A; Sethi A; Limbrick DD; Becher OJ; Tai YC; Rubin JB; Chen H; Liu Y
ACS Appl Nano Mater; 2020 Nov; 3(11):11129-11134. PubMed ID: 34337344
[TBL] [Abstract][Full Text] [Related]
18. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
19. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
[TBL] [Abstract][Full Text] [Related]
20. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
Chen J; Lin Z; Barrett L; Dai L; Qin Z
Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]